Astra Zeneca is the first company to move to Mind in Milan, the innovation district born on the “ashes” of Expo 2015. By choosing it as its new headquarters, the Anglo-Swedish pharmaceutical company aims to “fit into a research ecosystem” with the aim of accelerating innovation.
Also on investments, which from 24 million euros dedicated to research and development will go to 48 million euros, “thus doubling the benefits for the National Health Service to over 200 million”.
These are some of the data contained in the “AZ Valore” document, developed by The European House – Ambrosetti, with which the multinational illustrated its commitment and the production of value for Italy: 2 billion in contribution to GDP in the next 3 years, 3 thousand jobs activated on the supply chain in 2020 which will become 6,000 in 2023.
The document was presented today during an institutional event held at the Milano Innovation District, which originates from the reconversion of the Expo buildings according to circular economy principles. “Mind’s ecosystem will allow us to accelerate the development of ideas and their transformation into concrete projects to support patients and the whole society – says Lorenzo Wittum, president and CEO of AstraZeneca – We are convinced that innovation and research are needed. collaboration, simplification and that the contamination between different worlds is fundamental “.
Astra Zeneca is engaged in various therapeutic areas: oncology, cardiovascular, metabolic and renal, respiratory and immunological, infectious disease and vaccines, rare diseases. “In oncology we are committed to identifying therapeutic solutions for the treatment of 11 onco-haematological diseases – specifies Cristian Massacesi, Chief Medical Officer & Oncology Chief Development Officer of AstraZeneca – With the doubling of the current investments in Research and Development (48 million investments expected by 2023) we aim to do even more ».